Diagnostic workup of hepatitis C and the patient on maintenance dialysis

International Journal of Artificial Organs

Volumn 24, Issue 12, 2001, Pages 843-852

  Fabrizi, F ^a   Poordad, F F ^a   Martin, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C;

DIALYSIS;

HEPATITIS C ANTIBODY; HEPATITIS C CORE ANTIBODY; HYBRID PROTEIN; INTERFERON; RIBAVIRIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANTIBODY DETECTION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CLINICAL TRIAL; CONTAMINATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIALYSIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOBLOTTING; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; MOLECULAR TYPING; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; QUALITATIVE ANALYSIS; QUANTITATIVE ASSAY; RELIABILITY; REPRODUCIBILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; VIRAL GENETICS; VIREMIA; VIRUS GENOME; VIRUS LOAD;

EID: 0035717377     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880102401206     Document Type: Review

References (82)

1. Hepatitis C virus shares aminoacid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups
2. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
3. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
4. The natural history of community-acquired hepatitis C in the United States
5. Risk of death among chronic dialysis patients infected with hepatitis C virus
6. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy
7. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study
8. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients
9. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States
10. Serological and molecular testing in viral hepatitis: An update
11. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
12. Hepatitis C virus infection and hepatic function in chronic hemodialysis patients
13. Hepatitis C virus antibody in hemodialysis patients. Prevalence and risk factors
14. The prevalence of hepatitis C virus antibodies among hemodialysis patients
15. Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in hemodialysis patients
16. Prevalence of antibodies to hepatitis C virus in the hemodialysis unit
17. Prevalence of non-A, non-B hepatitis and anti-HCV antibodies in a Portoguese dialysis population
18. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients
19. Antibodies to hepatitis C virus in patients on haemodialysis
20. Antibody to hepatitis C virus increases with time on hemodialysis
21. High incidence of hepatitis C virus infection in hemodialysis patients
22. Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan
23. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members
24. Antibodies to hepatitis C virus and transaminase concentration in chronic haemodialysis patients: A study with second-generation assays
25. High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second-generation assay
26. Epidemiology of hepatitis C virus infection in dialysis units: First- versus second-generation assays
27. Prevalence of antibodies to hepatitis C virus in patients receiving renal replacement therapy and in the staff caring to them
28. Serological tests for HCV infection
29. Comparison of second-generation screening and confirmatory assays with recombinant antigens and synthetic peptides against antibodies to hepatitis C virus: A study in renal patients
30. Quantitative antibody responses to structural (core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: Impact of epitope variation and relationship to detection of HCV RNA in blood
31. Serologic survey for control of hepatitis C in haemodialysis patients: Third-generation assays and analysis of costs
32. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV RNA and anti-HCV antibodies (third-generation assays)
33. Confirmation of hepatitis C virus infection by new four antigen recombinant immunoblot assay
34. Evaluation of third-generation screening and confirmatory assays for HCV antibodies
35. Third-generation recombinant immunoblot assay to confirm hepatitis C virus-indeterminate serological samples
36. Failure of third-generation recombinant immunoblot assay to detect hepatitis C virus core antibodies
37. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
38. New insights into hepatitis C virus infection of hemodialysis patients: The implications
39. Evaluation of a novel serotyping system for hepatitis C virus: Strong correlation with standard genotyping methodologies
40. Automated RIBA™ HCV Strip Immunoblot Assay for reproducible diagnosis
41. Automated RIBA™ HCV Strip Immunoblot Assay: A novel tool for the diagnosis of hepatitis C virus infection in hemodialysis patients
42. Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients
43. IgM antibody response to hepatitis C virus in end-stage renal disease
44. Recommendations for preventing transmission of infections among chronic hemodialysis patients
45. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group
46. Second generation of the automated cobas amplicor HCV assay improves sensitivity of hepatitis C virus RNA
47. Measuring hepatitis C viremia in clinical samples: Can we trust the assays?
48. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection
49. Serum hepatitis C virus RNA in anti-HCV negative hemodialysis patients
50. Quantitative assessment of HCV load in chronic hemodialysis patients: A cross-sectional survey
51. Absence of HCV viraemia in anti-HCV negative haemodialysis patients
52. Acquisition of hepatitis C virus in hemodialysis patients: A prospective study by branched DNA signal amplification assay
53. Biologycal dynamics of viral load in hemodialysis patients with hepatitis C virus
54. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
55. Quantification of hepatitis C viral RNA in sera of hemodialysis patients: Gender-related differences in viral load
56. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection
57. Factors predictive of a beneficial response to therapy of hepatitis C
58. Future directions in the treatment of patients with chronic hepatitis C viral infection
59. Early predictors of response to treatment in patients with chronic hepatitis C
60. Real-time detection system for quantification of hepatitis C virus genome
61. High-throughout real-time reverse transcription-PCR quantitation of hepatitis C virus RNA
62. Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay
63. A proposed system for nomenclature of hepatitis C viral genomes
64. The changing relative prevalence of hepatitis C virus genotypes: Evidence in hemodialyzed patients and kidney recipients
65. Comparisons of hepatitis C virus strains obtained from hemodialysis patients
66. Hepatitis C virus genotypes in chronic dialysis patients
67. Molecular epidemiology of hepatitis C virus infection in dialysis patients
68. Prevalence and clinical expression of HCV-genotypes in haemodialysis patients of two geographically remote countries: Belgium and Saudi Arabia
69. Hepatitis C virus genotypes in hemodialyzed patients: A multicentre study
70. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
71. Clinical background of the patients having different types of hepatitis C virus genomes
72. Typing of hepatitis C virus genomes by restriction fragment length polymorphism
73. Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay
74. Typing of HCV isolates and characterization of new subtypes using a line probe assay
75. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3
76. RIBA™ HCV serotyping Strip Immunoblot Assay (SIA) for assessing hepatitis C virus (HCV) strains in dialysis patients: Strong association with genotyping technology
77. Relationship between hepatocellular carcinoma and subtypes of hepatitis C virus: A nationwide analysis
78. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection
79. Hepatitis C genotypes: The key to pathogenicity?
80. Severity of liver disease in liver transplant recipients with hepatitis C virus infection: Relationship to genotypes and level of viremia
81. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
82. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial